Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655209 | 0.82 | NPC1 (0.65) | NPC1RAB9APOLBSMN1; SMN2HPGD | |
| SCHEMBL8288031 | 0.80 | NPC1 (0.70) | NPC1RAB9APOLBSMN1; SMN2HPGD | |
| SCHEMBL6356707 | 0.80 | NPC1 (1.00) | NPC1RAB9APOLBSMN1; SMN2HPGD | |
| SCHEMBL1577945 | 0.80 | SMN1; SMN2 (0.75) | NPC1RAB9APOLBSMN1; SMN2HPGD | |
| SCHEMBL4769824 | 0.78 | SMN1; SMN2 (0.67) | NPC1RAB9ASMN1; SMN2HTTLMNA | |
| SCHEMBL5860823 | 0.77 | NPC1 (0.71) | NPC1RAB9APOLBHPGDKMT2A | |
| SCHEMBL2989489 | 0.77 | NPC1 (0.71) | NPC1RAB9APOLBSMN1; SMN2HPGD | |
| SCHEMBL28107072 | 0.77 | ALDH1A1 (0.51) | NPC1RAB9APOLBSMN1; SMN2HPGD | |
| SCHEMBL23416782 | 0.76 | TAAR1 (0.46) | NPC1RAB9APOLBSMN1; SMN2HPGD | |
| SCHEMBL13033025 | 0.76 | SMN1; SMN2 (0.60) | POLBSMN1; SMN2HPGDHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | CASE WESTERN RESERVE UNIVERSITY | 2013-06-20 | — | — | US | disclosed |
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | CASE WESTERN RESERVE UNIVERSITY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | IAPP, APP, BACE1 | NPC1 328/4885RAB9A 2823/4885POLB 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.